Follistatin

Follistatin is a naturally occurring glycoprotein that functions as a potent inhibitor of myostatin, activin, and other members of the TGF-β superfamily. Produced primarily in the liver, skin, and reproductive tissues, follistatin binds and neutralizes myostatin — the body's primary negative regulator of muscle growth — effectively removing the "brake" on muscle hypertrophy. The two main isoforms, FS315 (tissue-bound) and FS344 (circulating), have different tissue distributions and potencies. Gene therapy and recombinant follistatin have demonstrated dramatic muscle growth in animal models, including the famous "mighty mice" experiments showing 100-200% increases in muscle mass. Follistatin gene therapy has entered early clinical trials for muscular dystrophy.

Follistatin binds myostatin and activin with high affinity, preventing their interaction with ActRIIB (activin receptor type IIB). Myostatin normally signals through ActRIIB→Smad2/3 to suppress muscle protein synthesis and satellite cell activation. By neutralizing myostatin, follistatin removes this inhibition, allowing mTOR-mediated protein synthesis and satellite cell proliferation to proceed unchecked, resulting in marked muscle hypertrophy and hyperplasia.

Muscular Dystrophy Gene therapy using AAV-follistatin has entered Phase 1/2 clinical trials for Becker and Duchenne muscular dystrophy, showing improved muscle function and 6-minute walk test performance. Muscle Wasting Research for sarcopenia, cachexia, and disuse atrophy. Follistatin's myostatin-blocking mechanism promotes muscle growth even in catabolic conditions. Fertility Research Activin/follistatin balance regulates FSH secretion and follicular development, with implications for fertility treatment. Metabolic Improvement Follistatin-induced muscle mass increase enhances glucose disposal and insulin sensitivity through increased metabolic sink tissue.

Myostatin/ActRIIB/Smad2/3 inhibition. Released mTOR/p70S6K for protein synthesis. Enhanced satellite cell proliferation through removed Smad-mediated cell cycle inhibition. Activin neutralization for reproductive and metabolic effects.

Limited human safety data. Theoretical concerns include potential effects on reproductive hormones (activin/FSH regulation), liver function, and uncontrolled tissue growth. Gene therapy trials show acceptable safety profiles in muscular dystrophy patients. As a research compound, comprehensive side effect data is not available.

Follistatin is a large glycoprotein requiring careful handling. Store lyophilized form at -20°C or below. Reconstitute in sterile buffer with carrier protein (0.1% BSA). Use within 7 days at 2-8°C. Sensitive to freeze-thaw, agitation, and temperature extremes. Gene therapy approaches avoid protein stability challenges.

Not FDA-approved as a therapeutic protein. Gene therapy vectors expressing follistatin (AAV1-FS344) are in clinical trials under IND status for muscular dystrophy. Research compound. WADA-prohibited under S4.2 (Myostatin Inhibitors).